Chen an colleagues [50] found that knockdown of ALDH1A3 expression in human cholangiocarcinoma cell lines markedly reduced not only their sensitivity to gemcitabine, but also their migration, and most importantly, this enzyme was also identified as an independent poor prognostic factor for patients with intrahepatic cholangiocarcinoma, as well as a prognostic biomarker of gemcitabine-treated patients. The gene discussed is ALDH1A3; the disease is intrahepatic cholangiocarcinoma.